ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid

BiotechTV - News - ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid